Wilson Mark Andrew 4
4 · NEKTAR THERAPEUTICS · Filed Aug 21, 2025
Insider Transaction Report
Form 4
Wilson Mark Andrew
Chief Legal Officer
Transactions
- Sale
Common Stock
2025-08-19$26.59/sh−676$17,975→ 20,312 total - Award
Stock Option
2025-08-19+21,666→ 21,666 totalExercise: $0.50Exp: 2031-12-12→ Common Stock (21,666 underlying)
Footnotes (6)
- [F1]Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
- [F2]This transaction was executed in multiple trades at prices ranging from $26.19 to $27.15 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
- [F3]This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c).
- [F4]On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
- [F5]These stock options were granted on December 13, 2023 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant.
- [F6]The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 17, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on August 19, 2025 (subject to remaining time-based vesting requirements).